(Q60482582)

13 March 2019

22 March 2019

3 April 2019

on focus list of Wikimedia project

17 June 2019

ScienceSource

0 references

cites work

Osteoclast-like cell formation by circulating myeloma B lymphocytes: role of RANK-L.

1 reference

12 December 2020

Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma

1 reference

12 December 2020

Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

Wnt signaling in osteoblasts and bone diseases

1 reference

12 December 2020

Direct bone resorbing activity of murine myeloma cells

1 reference

12 December 2020

Computed tomography in diagnosis and management of multiple myeloma and its variants

1 reference

12 December 2020

Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease

1 reference

12 December 2020

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

1 reference

12 December 2020

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma

1 reference

12 December 2020

Development of an in vivo model of human multiple myeloma bone disease

1 reference

12 December 2020

Biochemical bone markers in patients with multiple myeloma.

1 reference

12 December 2020

Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis

1 reference

12 December 2020

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

1 reference

12 December 2020

Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.

1 reference

12 December 2020

Functional osteoclast-like transformation of cultured human myeloma cell lines.

1 reference

12 December 2020

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

12 December 2020

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

12 December 2020

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

1 reference

12 December 2020

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

1 reference

12 December 2020

Myeloma and bone disease: "the dangerous tango".

1 reference

12 December 2020

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass

1 reference

12 December 2020

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia

1 reference

12 December 2020

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

12 December 2020

Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?

1 reference

12 December 2020

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

1 reference

12 December 2020

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

1 reference

12 December 2020

Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma

1 reference

12 December 2020

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications

1 reference

12 December 2020

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations

1 reference

12 December 2020

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

1 reference

12 December 2020

Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF

1 reference

12 December 2020

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

1 reference

12 December 2020

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

12 December 2020

The pathogenesis of the bone disease of multiple myeloma.

1 reference

12 December 2020

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

1 reference

12 December 2020

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

1 reference

12 December 2020

Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand

1 reference

12 December 2020

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

1 reference

12 December 2020

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma

1 reference

12 December 2020

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients

1 reference

12 December 2020

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

12 December 2020

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

12 December 2020

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

1 reference

12 December 2020

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

12 December 2020

Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography

1 reference

12 December 2020

Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma

1 reference

12 December 2020

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

1 reference

12 December 2020

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

1 reference

12 December 2020

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

12 December 2020

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.

1 reference

12 December 2020

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

1 reference

12 December 2020

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

12 December 2020

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

1 reference

12 December 2020

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease

1 reference

12 December 2020

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo

1 reference

12 December 2020

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma

1 reference

12 December 2020

New Insights in Myeloma-induced Osteolysis

1 reference

12 December 2020

High heparanase activity in multiple myeloma is associated with elevated microvessel density

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Fracture risk in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma

1 reference

12 December 2020

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

1 reference

12 December 2020

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

1 reference

12 December 2020

Pathogenesis of myeloma bone disease

1 reference

12 December 2020

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling

1 reference

12 December 2020

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

1 reference

12 December 2020

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

1 reference

12 December 2020

beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells

1 reference

12 December 2020